Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Given Average Rating of "Moderate Buy" by Analysts

Jazz Pharmaceuticals plc (NASDAQ:JAZZ - Get Free Report) has received an average rating of "Moderate Buy" from the fifteen analysts that are covering the firm, Marketbeat Ratings reports. Two equities research analysts have rated the stock with a hold recommendation and thirteen have assigned a buy recommendation to the company. The average twelve-month price target among analysts that have covered the stock in the last year is $177.00.

JAZZ has been the subject of a number of analyst reports. TD Cowen decreased their target price on shares of Jazz Pharmaceuticals from $200.00 to $195.00 and set a "buy" rating for the company in a research report on Thursday, November 7th. Royal Bank of Canada reissued an "outperform" rating and issued a $179.00 price objective on shares of Jazz Pharmaceuticals in a research report on Tuesday, December 10th. HC Wainwright restated a "buy" rating and set a $200.00 target price on shares of Jazz Pharmaceuticals in a research note on Friday, November 22nd. Morgan Stanley upgraded Jazz Pharmaceuticals from an "equal weight" rating to an "overweight" rating and increased their price target for the company from $140.00 to $175.00 in a research note on Thursday, December 12th. Finally, Piper Sandler restated an "overweight" rating and set a $163.00 price target on shares of Jazz Pharmaceuticals in a research note on Thursday, December 12th.

Jazz Pharmaceuticals Stock Down 0.5 %

Jazz Pharmaceuticals stock traded down $0.68 during trading hours on Tuesday, reaching $124.37. The stock had a trading volume of 659,381 shares, compared to its average volume of 497,707. The company has a market cap of $7.52 billion, a price-to-earnings ratio of 17.52, a PEG ratio of 0.90 and a beta of 0.56. The business's 50 day moving average price is $122.74 and its 200-day moving average price is $115.83. Jazz Pharmaceuticals has a 52 week low of $99.06 and a 52 week high of $134.17. The company has a debt-to-equity ratio of 1.46, a current ratio of 4.26 and a quick ratio of 3.74.

Insider Activity at Jazz Pharmaceuticals

In related news, EVP Neena M. Patil sold 3,700 shares of the business's stock in a transaction on Friday, November 8th. The shares were sold at an average price of $123.41, for a total value of $456,617.00. Following the completion of the transaction, the executive vice president now directly owns 33,048 shares in the company, valued at $4,078,453.68. The trade was a 10.07 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CEO Bruce C. Cozadd sold 1,500 shares of the stock in a transaction on Thursday, January 2nd. The stock was sold at an average price of $123.43, for a total transaction of $185,145.00. Following the sale, the chief executive officer now directly owns 425,525 shares in the company, valued at $52,522,550.75. This trade represents a 0.35 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 7,253 shares of company stock worth $890,594 over the last three months. Company insiders own 4.20% of the company's stock.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the company. CIBC Asset Management Inc increased its stake in shares of Jazz Pharmaceuticals by 5.2% in the 4th quarter. CIBC Asset Management Inc now owns 1,972 shares of the specialty pharmaceutical company's stock valued at $243,000 after purchasing an additional 97 shares in the last quarter. GAMMA Investing LLC increased its position in shares of Jazz Pharmaceuticals by 41.3% in the third quarter. GAMMA Investing LLC now owns 414 shares of the specialty pharmaceutical company's stock valued at $46,000 after buying an additional 121 shares in the last quarter. UMB Bank n.a. raised its stake in shares of Jazz Pharmaceuticals by 70.9% during the 4th quarter. UMB Bank n.a. now owns 311 shares of the specialty pharmaceutical company's stock worth $38,000 after buying an additional 129 shares during the period. Ellsworth Advisors LLC lifted its position in shares of Jazz Pharmaceuticals by 0.4% during the 4th quarter. Ellsworth Advisors LLC now owns 37,962 shares of the specialty pharmaceutical company's stock valued at $4,675,000 after buying an additional 149 shares in the last quarter. Finally, Exchange Traded Concepts LLC grew its stake in Jazz Pharmaceuticals by 2.2% in the 4th quarter. Exchange Traded Concepts LLC now owns 7,045 shares of the specialty pharmaceutical company's stock valued at $868,000 after acquiring an additional 155 shares during the period. Institutional investors and hedge funds own 89.14% of the company's stock.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.